DHR
NYSE · Life Sciences Tools & Services
Danaher Corp
$230.16
-2.00 (-0.86%)
Financial Highlights (FY 2026)
Revenue
23.79B
Net Income
3.50B
Gross Margin
59.2%
Profit Margin
14.7%
Rev Growth
-2.7%
D/E Ratio
0.35
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 59.2% | 59.2% | 33.1% | 33.1% |
| Operating Margin | 19.2% | 17.3% | 22.8% | 20.7% |
| Profit Margin | 14.7% | 14.0% | 16.1% | 14.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 23.79B | 24.44B | 64.73B | 56.82B |
| Gross Profit | 14.09B | 14.48B | 21.40B | 18.79B |
| Operating Income | 4.56B | 4.22B | 14.74B | 11.75B |
| Net Income | 3.50B | 3.24B | 10.42B | 8.26B |
| Gross Margin | 59.2% | 59.2% | 33.1% | 33.1% |
| Operating Margin | 19.2% | 17.3% | 22.8% | 20.7% |
| Profit Margin | 14.7% | 14.0% | 16.1% | 14.5% |
| Rev Growth | -2.7% | -2.7% | +18.7% | +12.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 20.72B | 20.72B | 69.79B | 63.61B |
| Total Equity | 59.10B | 59.10B | 119.38B | 109.88B |
| D/E Ratio | 0.35 | 0.35 | 0.58 | 0.58 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 5.29B | 5.16B | 20.74B | 18.10B |
| Free Cash Flow | — | — | 7.59B | 7.26B |